688139 海尔生物
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)5.5249.84315.72026.41314.570
总资产报酬率 ROA (%)4.2187.37311.56619.11310.912
投入资产回报率 ROIC (%)5.1138.89113.68322.56913.141

边际利润分析
销售毛利率 (%)48.27350.63448.15450.14550.492
营业利润率 (%)20.99219.22123.59245.22630.495
息税前利润/营业总收入 (%)18.85118.01722.87244.64029.234
净利润/营业总收入 (%)19.54918.06621.36739.94527.398

收益指标分析
经营活动净收益/利润总额(%)94.29772.25984.49845.53675.378
价值变动净收益/利润总额(%)3.92819.58410.02750.31622.109
营业外收支净额/利润总额(%)0.803-0.900-0.051-0.059-0.781

偿债能力分析
流动比率 (X)2.5682.6932.9453.0232.618
速动比率 (X)2.3072.4302.7172.7212.380
资产负债率 (%)19.49519.64924.42425.73729.374
带息债务/全部投入资本 (%)3.8164.5668.21911.59011.304
股东权益/带息债务 (%)2,433.0792,021.3901,074.899738.859753.738
股东权益/负债合计 (%)390.608389.669299.903287.278239.696
利息保障倍数 (X)-8.157-17.463-32.301-79.864-28.528

营运能力分析
应收账款周转天数 (天)42.62927.10816.85020.93431.922
存货周转天数 (天)70.12282.89874.708100.83191.680